Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.

Future oncology (London, England) - 1 Jan 2020

Nemunaitis John, Bauer Sebastian, Blay Jean-Yves, Choucair Khalil, Gelderblom Hans, George Suzanne, Schöffski Patrick, Mehren Margaret von, Zalcberg John, Achour Haroun, Ruiz-Soto Rodrigo, Heinrich Michael C

Abstract excerpt

Ripretinib (DCC-2618) is a novel, type II tyrosine switch control inhibitor designed to broadly inhibit activating and drug-resistant mutations in KIT and PDGFRA. Ripretinib has emerged as a promising investigational agent for the treatment of gastrointestinal stromal tumor owing to targeted inhibition of secondary resistance mutations that may develop following treatment with prior line(s) of tyrosine kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastrointestinal Neoplasms
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Naphthyridines

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Research Design

Share to Sunitinib

Source

Identifiers

PMID: 31755321
DOI: 10.2217/fon-2019-0633

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.PMID 31755321Read ↗

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.Semantic proximity Read ↗

Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.Semantic proximity Read ↗

The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.Semantic proximity Read ↗

An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

Emerging drugs for the treatment of gastrointestinal stromal tumors.Semantic proximity Read ↗

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.Semantic proximity Read ↗

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study.Semantic proximity Read ↗

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.Semantic proximity Read ↗

Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy.Semantic proximity Read ↗

New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Gastrointestinal Stromal Tumor: Current Approaches and Future Directions in the Treatment of Advanced Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.